Research and Markets - Global Premature Ejaculation Treatment Market CAGR Growth of 9.65% by 2020 - Trends, Technologies & Opportunities Report 2016-2020 - Key Vendors: Pfizer, Emcure, Eli Lilly

News provided by

Aug 17, 2016, 09:10 ET

DUBLIN, August 17, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Premature Ejaculation Treatment Market 2016-2020" report to their offering.

The report forecasts the global premature ejaculation treatment market to grow at a CAGR of 9.65% during the period 2016-2020.

Commenting on the report, an analyst from the research team said: Increase in awareness of premature ejaculation will be a key trend for market growth. There has been an increase in awareness of premature ejaculation among patients and physicians. It is a trend that will gain prominence during the forecast period, driving the premature ejaculation treatment market. For instance, "PE Awareness" is a community that engages in spreading awareness of premature ejaculation among patients through its tools and resources.

The community has also taken steps to arrange funds for R&D of new medicines to treat the disorder. In addition, a campaign called "Firing Too Quickly," developed by Menarini Pharmaceuticals, helps patients understand the disorder and combat it. Another initiative by the Philippine Urological Association and A. Menarini Philippines involves a premature ejaculation advocacy campaign intended to create awareness of the basics of premature ejaculation. These awareness campaigns intend to educate people about the importance of addressing the issue through different treatment methods available in the market.

According to the report, high prevalence rate of cancer among men will be a key driver for market growth. Cancer is a probable cause of premature ejaculation among men. Cancer treatment can lead to a change in hormonal functioning and sex hormones (androgens such as testosterone), which eventually affects the libido and the ability of men to achieve orgasms during sexual intercourse. Generally, cancer requires treatments such as surgery, radiotherapy, and chemotherapy to completely eradicate the disease in the patient or to limit the spread of cancer cells. In many cases, chemotherapy among men has been known to impede the production of testosterone, thus affecting overall sexual response and desire. Therefore, the increase in the number of cases of cancer among men raises the probability of premature ejaculation cases.

Questions Answered:

What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What are the challenges to market growth?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Companies Mentioned:

Absorption Pharmaceuticals
Allergan
Innovus Pharmaceuticals
Plethora
Aytu BioScience
Bayer
Dong-A Pharmaceutical
Eli Lilly
Emcure
Futura Medical
GlaxoSmithKline
NeuroHealing Pharmaceuticals
Pfizer

Report Structure:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Market landscape

PART 06: Geographical segmentation

PART 07: Market segmentation by route of administration

PART 08: Market segmentation by mechanism of action

PART 09: Market segmentation by off-label drugs

PART 10: Market drivers

PART 11: Impact of drivers

PART 12: Market challenges

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape

PART 16: Key vendor analysis

PART 17: Appendix

PART 18: About the Author

For more information about this report visit http://www.researchandmarkets.com/research/jd77hb/global_premature

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets